News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Sep 16, 2021

Summary Toggle aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

SAN DIEGO , Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of 9,375,000
Sep 15, 2021

Summary Toggle aTyr Pharma Announces Proposed Public Offering of Common Stock

SAN DIEGO , Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has commenced an underwritten public offering of
Sep 13, 2021

Summary Toggle aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of steroids. Clinically meaningful improvements in forced vital
Aug 10, 2021

Summary Toggle aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021 . Company to host conference call and webcast today, August 10th , at 5:00 p.m. EDT / 2:00 p.m. PDT . SAN DIEGO , Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Aug 10, 2021

Summary Toggle aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University

Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO , Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, today announced that
Aug 9, 2021

Summary Toggle aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

SAN DIEGO , Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic candidate, ATYR1923,
Aug 3, 2021

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

Management to host conference call and webcast on August 10th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,
Jul 29, 2021

Summary Toggle aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

SAN DIEGO , July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent
Jul 8, 2021

Summary Toggle aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

Results from proof-of-concept study are expected in September 2021 . SAN DIEGO , July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that
Jun 23, 2021

Summary Toggle aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

Event will feature Dr. Daniel Culver , Director of the Interstitial Lung Disease Program at the Cleveland Clinic . Conference call and webcast scheduled for Tuesday June 29 th at 5:00pm ET / 2:00pm PT . SAN DIEGO , June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.